AstraZeneca Pharma India Ltd reported its unaudited financial results for the quarter ending September 30, 2024, showing total income of Rs 4,161.5 million and a net profit of Rs 384.3 million, while noting an estimated exit from its manufacturing site taking over 12 months and accounting for Rs 575.6 million as an exceptional item.